This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Waites, K. B.
Right arrow Articles by Duffy, L. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Waites, K. B.
Right arrow Articles by Duffy, L. B.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2008, p. 3776-3778, Vol. 52, No. 10
0066-4804/08/$08.00+0     doi:10.1128/AAC.00849-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Comparative In Vitro Activities of the Investigational Fluoroquinolone DC-159a and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas {triangledown}

Ken B. Waites,* Donna M. Crabb, and Lynn B. Duffy

Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama

Received 26 June 2008/ Accepted 14 July 2008

The in vitro susceptibilities of 151 unique clinical isolates of Mycoplasma pneumoniae, Mycoplasma hominis, Mycoplasma fermentans, Mycoplasma genitalium, and Ureaplasma species to DC-159a, an investigational fluoroquinolone, in comparison with those to other agents were determined. Macrolides were the most active agents against M. pneumoniae and M. genitalium, whereas clindamycin was most active against M. hominis. DC-159a MICs were ≤0.5 µg/ml for all Mycoplasma species and ≤4 µg/ml for ureaplasmas. DC-159a was the most active fluoroquinolone tested against M. pneumoniae and M. fermentans, and it was second to moxifloxacin against the other species. It was bactericidal against 10 M. pneumoniae isolates and demonstrated killing of ≥99.9% of the inoculum at 24 h for 2 isolates. The excellent in vitro activity of DC-159a demonstrates its potential for use in the treatment of infections due to mycoplasmas and ureaplasmas.

* Corresponding author. Mailing address: Department of Pathology WP 230, University of Alabama at Birmingham, 619n 19th St. South, Birmingham, AL 35249. Phone: (205) 934-4960. Fax: (205) 975-4468. E-mail: waites{at}path.uab.edu

{triangledown} Published ahead of print on 28 July 2008.

Antimicrobial Agents and Chemotherapy, October 2008, p. 3776-3778, Vol. 52, No. 10
0066-4804/08/$08.00+0     doi:10.1128/AAC.00849-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»